CoChat

Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

Open access
Meyers, Charles Daniel, Tremblay, Karine, Amer, Ahmed, Chen, Jin, Jiang, Liewen, Gaudet, Daniel · 2015 · Lipids in Health and Disease

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency resulting in fasting chylomicronemia and severe hypertriglyceridemia. Inhibition of diacylglycerol acyltransferase 1 (DGAT1), which mediates chylomicron triglyceride (TG) synthesis, is an attractive strategy to reduce TG levels in FCS. In this study we assessed the safety, tolerability and TG-lowering efficacy of the DGAT1 inhibitor pradigastat in patients with FCS. METHODS: Six FCS patients were enrolled in an open-label clinical study. Following a 1-week very low fat diet run-in period patients underwent baseline lipid assessments, including a low fat meal tolerance test. Patients then underwent three consecutive 21 day treatment periods (pradigastat at 20, 40 & 10 mg, respectively). Treatment periods were separated by washout periods of ≥4 weeks. Fasting TG levels were assessed weekly through the treatment periods. Postprandial TGs, ApoB48 and lipoprotein lipid content were also monitored. RESULTS: Following once daily oral dosing, steady-state exposure was reached by Day 14. There was an approximately dose proportional increase in pradigastat exposure at studied doses. Pradigastat was associated with a 41% (20 mg) and 70% (40 mg) reduction in fasting triglyceride over 21 days of treatment. The reduction in fasting TG was almost entirely accounted for by a reduction in chylomicron TG. Pradigastat treatment also led to substantial reductions in postprandial TG as well as apo48 (both fasting and postprandial). Pradigastat was safe and well tolerated, with only mild, transient gastrointestinal adverse events. CONCLUSION: The novel DGAT1 inhibitor pradigastat substantially reduces plasma TG levels in FCS patients, and may be a promising new treatment for this orphan disease. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01146522 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12944-015-0006-5

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fasting triglyceride levels during the treatment with pradigastat at different doses. Footnote: Data presented as geometric mean ± standard error of mean (SEM).
Figure 1 Fasting triglyceride levels during the treatment with pradigastat at different doses. Footnote: Data presented as geometric mean ± standard error of mean (SEM).CC BY · PubMed Central
Figure 2 Postprandial plasma triglyceride levels during the treatment with pradigastat at different doses. Footnote: Data presented as geometric mean ± standard error of mean (SEM). Percentage change compared with the 10 mg dose for postprandial TG AUC0–9 are shown by ‘↓’. TG, triglycerides; AUC0–9, area under curve over 0 to 9 hours of meal tolerance test. Panel A = TG concentration/time profile over 9 hours, Panel B = TG AUC0-9.
Figure 2 Postprandial plasma triglyceride levels during the treatment with pradigastat at different doses. Footnote: Data presented as geometric mean ± standard error of mean (SEM). Percentage change compared with the 10 mg dose for postprandial TG AUC0–9 are shown by ‘↓’. TG, triglycerides; AUC0–9, area under curve over 0 to 9 hours of meal tolerance test. Panel A = TG concentration/time profile over 9 hours, Panel B = TG AUC0-9.CC BY · PubMed Central
Figure 3 Dose comparison of fasting and postprandial apolipoprotein B48 levels. Footnote: Original ApoB48 values were expressed in ng/L for fasting and postprandial peak, and h*ng/mL for postprandial AUC0–9. This figure shows the Geometric least squares mean ratio of the end of treatment for each of the three dose levels to baseline. Percentage change compared with the 10 mg dose are shown by ‘↓’; * p < 0.05.
Figure 3 Dose comparison of fasting and postprandial apolipoprotein B48 levels. Footnote: Original ApoB48 values were expressed in ng/L for fasting and postprandial peak, and h*ng/mL for postprandial AUC0–9. This figure shows the Geometric least squares mean ratio of the end of treatment for each of the three dose levels to baseline. Percentage change compared with the 10 mg dose are shown by ‘↓’; * p < 0.05.CC BY · PubMed Central
Figure 4 Pradigastat plasma concentration-time profile. Footnote: Data presented as mean ± standard deviation.
Figure 4 Pradigastat plasma concentration-time profile. Footnote: Data presented as mean ± standard deviation.CC BY · PubMed Central
Figure 5 Study design.
Figure 5 Study design.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 1

  1. Upthagrove A, Einolf H, Hanna I, Bretz A, Wang L, Peng L: Disposition of pradigastat (LCQ908) in humans: in vivo and in vitro investigations. 2013

Cited by

See all 111

Metadata

Authors
Meyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D.
Affiliations
Université de Montréal (CA)
Corresponding author
Meyers, Charles Daniel
Venue
Lipids in Health and Disease
Published
2015-02-18
Volume
14
Issue
1
Pages
8-8
ISSN
1476-511X (ISSN-L)
OpenAlex
W2130127759
Cited by
110
References
18
Citations by year
2026: 7 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 7 · 2020: 12 · 2019: 11 · 2018: 13 · 2017: 12 · 2016: 13 · 2015: 5
FWCI
10.41
Type
journal article
Language
en
Open access
Locations
  • Lipids in Health and Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Heart and Stroke Foundation of Canada
  • Clinical Trial Center, China Medical University Hospital
  • Université de Montréal
  • Novartis Pharma
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
Keywords
DGAT1 inhibitors, familial chylomicronemia syndrome, lipoprotein lipase deficiency, hypertriglyceridemia, triglyceride-lowering therapy, apoB-48, postprandial triglycerides, drug safety and tolerability, rare diseases
MeSH terms
Acetates, Adult, Aged, Aminopyridines, Female, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Triglycerides, Diacylglycerol O-Acyltransferase, Apolipoprotein B-48

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. https://app.cochat.ai/papers/10.1186/s12944-015-0006-5
The paper
Meyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D. (2015). Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids in Health and Disease. https://doi.org/10.1186/s12944-015-0006-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.